2Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria,and non-insulin dependent diabetes:the candesartan and lisinopril microalbuminuria ( CLAM )study. BMJ ,2000.321 : 1440-1444.
3Mathiesen ER, Hommel E, Hansen HP, et al. Randomised controlled trial of long term efficacy of captopfil on preservation of kidney function in nonnotensive patients with insulin dependent diabetes and microalbuminufia. BMJ, 1999,319:24-25.
4Adler SG, Pahl M, Seldin MF.Deciphering diabetic nephropathy: progress using genetic strategies.Curr Opin Nephrol Hypertens,2000,9:99-106.
5Lansang MC, Hollenberg NK.Renal perfusion and the renal hemodynamic response to blocking the renin system in diabetes: are the forces leading to vasodilation and vasoconstriction linked?Diabetes,2002,51:2025-2028.
6Volker V, Roland CB, Scott T, et al. Glomerular hyperfiltration and the salt paradox in rarly type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol, 2003,14:530-537.
7Sheetz MJ, King GL.Molecular understanding of hyperglycemia's adverse effects for diabetic complications.JAMA,2002,288:2579-2588.
8Brownlee M. Biochemistry and molecular cell biology of diabetic complications.Nature,2001,414:813-820.
9Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.Diabetes,2002,51:3274-3282.
10Evans JL, Goldfine ID, Maddux BA,et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev, 2002,23:599-622.
